SCHEMBL23155481

SCHEMBL23155481

CS(=O)(=O)c1ccc(C(=O)OCc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 3/20 0.45
RAB9A P51151 3/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
MITF O75030 1/20 0.45
HTT P42858 1/20 0.45
CCR6 P51684 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
SLC6A9 P48067 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119506 0.84 ALDH1A1 (0.49) PTPN1ALDH1A1MAPK1RAB9AMAPT
SCHEMBL26376259 0.82 MAPT (0.52) ALDH1A1MAPK1RAB9AMAPTKMT2A
SCHEMBL663178 0.82 TDP1 (0.55) ALDH1A1MAPK1RAB9AKMT2ANPC1
SCHEMBL663577 0.81 ALDH1A1 (0.51) ALDH1A1MAPK1RAB9AMAPTKMT2A
SCHEMBL942785 0.80 KMT2A (0.49) ALDH1A1MAPK1RAB9AMAPTKMT2A
SCHEMBL20841682 0.80 ALDH1A1 (0.50) ALDH1A1MAPK1RAB9AMAPTKMT2A
SCHEMBL4421604 0.80 TDP1 (0.60) ALDH1A1MAPK1RAB9AMAPTKMT2A
SCHEMBL16127475 0.79 ALDH1A1 (0.63) ALDH1A1MAPK1RAB9AKMT2ALMNA
SCHEMBL15754766 0.75 HPGD (0.47) ALDH1A1MAPK1RAB9AKMT2ANPC1
SCHEMBL5191638 0.75 TDP1 (0.45) ALDH1A1MAPK1MAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 US disclosed
WO-2021061643-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS PTPN1 2303/4885ALDH1A1 1538/4885MAPK1 2448/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS PTPN1 2303/4885ALDH1A1 1538/4885MAPK1 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.